二硝酸2-苯基-9-二乙基咪唑[1,2-α]苯咪唑片剂的制备及其质量控制方法的开发

Q3 Pharmacology, Toxicology and Pharmaceutics Drug Development and Registration Pub Date : 2021-05-31 DOI:10.33380/2305-2066-2021-10-2-62-67
Ангелина Михайловна Доманина, Максим Валентинович Черников, Ирина Петровна Ремезова, Элеонора Федоровна Степанова, Александр Михайлович Шевченко, Артем Владимирович Морозов
{"title":"二硝酸2-苯基-9-二乙基咪唑[1,2-α]苯咪唑片剂的制备及其质量控制方法的开发","authors":"Ангелина Михайловна Доманина, Максим Валентинович Черников, Ирина Петровна Ремезова, Элеонора Федоровна Степанова, Александр Михайлович Шевченко, Артем Владимирович Морозов","doi":"10.33380/2305-2066-2021-10-2-62-67","DOIUrl":null,"url":null,"abstract":"Introduction. Currently, for the treatment of gastric ulcer, drugs with a combined effect are used. To eliminate possible side effects of the drugs used, the search for new molecules to create more effective and safe histamine H 2 receptors continues. As a possible solution to these problems, we investigated the substance dinitrate of 2-phenyl-9-diethylaminoethylimidazo[1,2-α]benzimidazole (DFDB). Aim. The aim of this study was to obtain 2-phenyl-9-diethylaminoethylimidazo[1,2-α]benzimidazole dinitrate tablets and develop methods for quality control. Materials and methods. The object of study was tablets based on the substance DF DB. The physicochemical and technological properties of the tablet dosage form were studied. Pharmaco-technological and physico-chemical indicators were determined according to the methods of the State Pharmacopoeia of the XIV edition. Identification and quantitative determination of DFDB in tablets was performed by HPLC. Results and discussion. Based on the physico-chemical properties and determination of the main technological indicators of DFDB, an optimal tableting technology has been developed. The optimal composition of tablets has been developed. Identification of tablets is proposed to be carried out using HPLC in comparison with the standard sample of DFDB. Related impurities, according to the data obtained, do not exceed 0.1 %. We found that the tablets do not have an antimicrobial effect. The analyzed tablets correspond to category 3A. The content of DFDB should be from 95 to 105 % of the declared amount in one tablet. During the analysis, we conducted biopharmaceutical and technological studies of the finished dosage form during storage under the conditions of long-term stability testing in polymer cans with screw-on lids. It is shown that the selected composition of excipients and the production technology ensure the stability of the finished dosage form for two years of storage under the observed conditions. To select the tableting technology, the main technological properties of the DFDB substance are analyzed. The choice of excipients and the composition of the film coating was carried out. Conclusion. The technology is developed and standardization of tablets based on the substance DFDB is proposed.","PeriodicalId":36465,"journal":{"name":"Drug Development and Registration","volume":"10 1","pages":"62-67"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Получение таблеток динитрата 2-фенил-9-диэтиламиноэтилимидазо[1,2-α]бензимидазола и разработка методик контроля их качества\",\"authors\":\"Ангелина Михайловна Доманина, Максим Валентинович Черников, Ирина Петровна Ремезова, Элеонора Федоровна Степанова, Александр Михайлович Шевченко, Артем Владимирович Морозов\",\"doi\":\"10.33380/2305-2066-2021-10-2-62-67\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction. Currently, for the treatment of gastric ulcer, drugs with a combined effect are used. To eliminate possible side effects of the drugs used, the search for new molecules to create more effective and safe histamine H 2 receptors continues. As a possible solution to these problems, we investigated the substance dinitrate of 2-phenyl-9-diethylaminoethylimidazo[1,2-α]benzimidazole (DFDB). Aim. The aim of this study was to obtain 2-phenyl-9-diethylaminoethylimidazo[1,2-α]benzimidazole dinitrate tablets and develop methods for quality control. Materials and methods. The object of study was tablets based on the substance DF DB. The physicochemical and technological properties of the tablet dosage form were studied. Pharmaco-technological and physico-chemical indicators were determined according to the methods of the State Pharmacopoeia of the XIV edition. Identification and quantitative determination of DFDB in tablets was performed by HPLC. Results and discussion. Based on the physico-chemical properties and determination of the main technological indicators of DFDB, an optimal tableting technology has been developed. The optimal composition of tablets has been developed. Identification of tablets is proposed to be carried out using HPLC in comparison with the standard sample of DFDB. Related impurities, according to the data obtained, do not exceed 0.1 %. We found that the tablets do not have an antimicrobial effect. The analyzed tablets correspond to category 3A. The content of DFDB should be from 95 to 105 % of the declared amount in one tablet. During the analysis, we conducted biopharmaceutical and technological studies of the finished dosage form during storage under the conditions of long-term stability testing in polymer cans with screw-on lids. It is shown that the selected composition of excipients and the production technology ensure the stability of the finished dosage form for two years of storage under the observed conditions. To select the tableting technology, the main technological properties of the DFDB substance are analyzed. The choice of excipients and the composition of the film coating was carried out. Conclusion. The technology is developed and standardization of tablets based on the substance DFDB is proposed.\",\"PeriodicalId\":36465,\"journal\":{\"name\":\"Drug Development and Registration\",\"volume\":\"10 1\",\"pages\":\"62-67\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Development and Registration\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33380/2305-2066-2021-10-2-62-67\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Development and Registration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33380/2305-2066-2021-10-2-62-67","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 1

摘要

介绍。目前,胃溃疡的治疗多采用联合作用的药物。为了消除所使用药物可能产生的副作用,研究人员仍在继续寻找新的分子来制造更有效、更安全的组胺h2受体。为了解决这些问题,我们研究了2-苯基-9-二乙基氨基乙基咪唑[1,2-α]苯并咪唑(DFDB)的硝酸盐物质。的目标。本研究的目的是制备2-苯基-9-二乙基氨基乙基咪唑[1,2-α]硝基苯并咪唑片,并建立质量控制方法。材料和方法。研究对象为以DF - DB为基材的片剂。研究了片剂剂型的理化性能和工艺性能。药工艺指标和理化指标按《国家药典》第十四版的方法测定。采用高效液相色谱法对片剂中DFDB的含量进行鉴别和定量测定。结果和讨论。通过对DFDB的理化性质和主要工艺指标的测定,确定了最佳压片工艺。确定了片剂的最佳组成。建议采用高效液相色谱法对片剂进行鉴别,并与标准品DFDB进行比较。根据获得的数据,相关杂质不超过0.1%。我们发现这些药片没有抗菌作用。所分析的片剂属于3A类。片剂中DFDB的含量应为申报量的95% ~ 105%。在分析过程中,我们对成品剂型进行了生物制药和工艺方面的研究,并对成品剂型进行了长期稳定性测试的条件下,将其保存在具有螺旋盖的聚合物罐中。结果表明,所选择的辅料组成和生产工艺保证了成品剂型在观察条件下的稳定性,可保存两年。为了选择压片工艺,分析了DFDB物质的主要工艺性能。对赋形剂的选择和薄膜涂层的组成进行了研究。结论。开发了基于物质DFDB的片剂制备技术,并提出了片剂的标准化方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Получение таблеток динитрата 2-фенил-9-диэтиламиноэтилимидазо[1,2-α]бензимидазола и разработка методик контроля их качества
Introduction. Currently, for the treatment of gastric ulcer, drugs with a combined effect are used. To eliminate possible side effects of the drugs used, the search for new molecules to create more effective and safe histamine H 2 receptors continues. As a possible solution to these problems, we investigated the substance dinitrate of 2-phenyl-9-diethylaminoethylimidazo[1,2-α]benzimidazole (DFDB). Aim. The aim of this study was to obtain 2-phenyl-9-diethylaminoethylimidazo[1,2-α]benzimidazole dinitrate tablets and develop methods for quality control. Materials and methods. The object of study was tablets based on the substance DF DB. The physicochemical and technological properties of the tablet dosage form were studied. Pharmaco-technological and physico-chemical indicators were determined according to the methods of the State Pharmacopoeia of the XIV edition. Identification and quantitative determination of DFDB in tablets was performed by HPLC. Results and discussion. Based on the physico-chemical properties and determination of the main technological indicators of DFDB, an optimal tableting technology has been developed. The optimal composition of tablets has been developed. Identification of tablets is proposed to be carried out using HPLC in comparison with the standard sample of DFDB. Related impurities, according to the data obtained, do not exceed 0.1 %. We found that the tablets do not have an antimicrobial effect. The analyzed tablets correspond to category 3A. The content of DFDB should be from 95 to 105 % of the declared amount in one tablet. During the analysis, we conducted biopharmaceutical and technological studies of the finished dosage form during storage under the conditions of long-term stability testing in polymer cans with screw-on lids. It is shown that the selected composition of excipients and the production technology ensure the stability of the finished dosage form for two years of storage under the observed conditions. To select the tableting technology, the main technological properties of the DFDB substance are analyzed. The choice of excipients and the composition of the film coating was carried out. Conclusion. The technology is developed and standardization of tablets based on the substance DFDB is proposed.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Drug Development and Registration
Drug Development and Registration Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
1.20
自引率
0.00%
发文量
61
审稿时长
8 weeks
期刊最新文献
Medicinal Perspectives of Retinoids (Review) End-to-end Standardization of Original Medicines when Determining Related Impurities Development of Amlodipine Mini-tablets as a Polypill-component for the Personalized Therapy of Arterial Hypertension Composition and Technology Development for Obtaining Amorphous Solid Dispersion of Ebastine by Hot Melt Extrusion to Increase Dissolution Rate Could Bioluminescent Bacteria be Used in the Search for New Plant-derived Antibacterial Substances?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1